請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45080
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳秀熙(Tony Hsiu-Hsi Chen),林肇堂(Jaw-Town Lin) | |
dc.contributor.author | Han-Mo Chiu | en |
dc.contributor.author | 邱瀚模 | zh_TW |
dc.date.accessioned | 2021-06-15T04:03:42Z | - |
dc.date.available | 2015-03-12 | |
dc.date.copyright | 2010-03-12 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-02-11 | |
dc.identifier.citation | 1. WHO WHO. Global cancer rates could increase by 50% to 15 million by 2020-The World Cancer Report – The major findings. 2003;http://www.who.int/mediacentre/news/releases/2003/pr27/en/.Jan. 15 2010.
2. Parkin DM WS, Ferlay J et al. Cancer Incidence in Five Continents, Vol. VIII. . IARC CancerBase No. 7. Lyon: International Agency for Research on Cancer. IARC Scientific Publications, No. 155, 2005. 3. Sung JJ, Lau JY, Goh KL, et al. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005;6:871-6. 4. Taiwan Cancer Registry. 2009;http://tcr.cph.ntu.edu.tw/main.php?Page=N1.Jan,15 2010. 5. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5. 6. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology 2006;130:1872-85. 7. Imperiale TF, Wagner DR, Lin CY, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000;343:169-74. 8. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000;343:162-8. 9. Byeon JS, Yang SK, Kim TI, et al. Colorectal neoplasm in asymptomatic Asians: a prospective multinational multicenter colonoscopy survey. Gastrointest Endosc 2007;65:1015-22. 10. Imperiale TF, Wagner DR, Lin CY, et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002;346:1781-5. 11. Leung WK, Ho KY, Kim WH, et al. Colorectal neoplasia in Asia: a multicenter colonoscopy survey in symptomatic patients. Gastrointest Endosc 2006;64:751-9. 12. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 2006;355:1863-72. 13. Rex DK, Khan AM, Shah P, et al. Screening colonoscopy in asymptomatic average-risk African Americans. Gastrointest Endosc 2000;51:524-7. 14. Chiu HM, Wang HP, Lee YC, et al. A prospective study of the frequency and the topographical distribution of colon neoplasia in asymptomatic average-risk Chinese adults as determined by colonoscopic screening. Gastrointest Endosc 2005;61:547-53. 15. Liu HH, Wu MC, Peng Y, et al. Prevalence of advanced colonic polyps in asymptomatic Chinese. World J Gastroenterol 2005;11:4731-4. 16. Soon MS, Kozarek RA, Ayub K, et al. Screening colonoscopy in Chinese and Western patients: a comparative study. Am J Gastroenterol 2005;100:2749-55. 17. Chiu HM, Lin JT, Chen CC, et al. Prevalence and characteristics of nonpolypoid colorectal neoplasm in an asymptomatic and average-risk Chinese population. Clin Gastroenterol Hepatol 2009;7:463-70. 18. Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70. 19. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32. 20. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60. 21. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993;329:1977-81. 22. Shimoda T, Ikegami M, Fujisaki J, et al. Early colorectal carcinoma with special reference to its development de novo. Cancer 1989;64:1138-46. 23. Kudo S, Tamura S, Hirota S, et al. The problem of de novo colorectal carcinoma. Eur J Cancer 1995;31A:1118-20. 24. Muto T, Kamiya J, Sawada T, et al. Small 'flat adenoma' of the large bowel with special reference to its clinicopathologic features. Dis Colon Rectum 1985;28:847-51. 25. Yang KC, Liao CS, Chiu YH, et al. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan. J Med Screen 2006;13 Suppl 1:S8-13. 26. Matsui T, Yao T, Iwashita A. Natural history of early colorectal cancer. World J Surg 2000;24:1022-8. 27. Jaramillo E, Watanabe M, Slezak P, et al. Flat neoplastic lesions of the colon and rectum detected by high-resolution video endoscopy and chromoscopy. Gastrointest Endosc 1995;42:114-22. 28. Rembacken BJ, Fujii T, Cairns A, et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonoscopies in the UK. Lancet 2000;355:1211-4. 29. Saitoh Y, Waxman I, West AB, et al. Prevalence and distinctive biologic features of flat colorectal adenomas in a North American population. Gastroenterology 2001;120:1657-65. 30. Tsuda S, Veress B, Toth E, et al. Flat and depressed colorectal tumours in a southern Swedish population: a prospective chromoendoscopic and histopathological study. Gut 2002;51:550-5. 31. Chen CD, Yen MF, Wang WM, et al. A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer 2003;88:1866-73. 32. Goto H, Oda Y, Murakami Y, et al. Proportion of de novo cancers among colorectal cancers in Japan. Gastroenterology 2006;131:40-6. 33. Kudo S, Lambert R, Allen JI, et al. Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc 2008;68:S3-47. 34. Soetikno RM, Kaltenbach T, Rouse RV, et al. Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008;299:1027-35. 35. Lieberman D. Nonpolypoid colorectal neoplasia in the United States: the parachute is open. JAMA 2008;299:1068-9. 36. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17. 37. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2009. 38. Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med 1995;122:327-34. 39. Giovannucci E, Colditz GA, Stampfer MJ, et al. Physical activity, obesity, and risk of colorectal adenoma in women (United States). Cancer Causes Control 1996;7:253-63. 40. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007;132:2208-25. 41. Tsoi KK, Pau CY, Wu WK, et al. Cigarette smoking and the risk of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2009;7:682-688 e1-5. 42. Tung SY, Wu CS. Risk factors for colorectal adenomas among immediate family members of patients with colorectal cancer in Taiwan: a case-control study. Am J Gastroenterol 2000;95:3624-8. 43. Limburg PJ, Anderson KE, Johnson TW, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2005;14:133-7. 44. Seow A, Yuan JM, Koh WP, et al. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J Natl Cancer Inst 2006;98:135-8. 45. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202. 46. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001;285:2486-97. 47. Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006;107:28-36. 48. Colangelo LA, Gapstur SM, Gann PH, et al. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002;11:385-91. 49. Chiu HM, Lin JT, Shun CT, et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol Hepatol 2007;5:221-9; quiz 141. 50. Chiu HM, Lin JT, Chen TH, et al. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol 2008;103:2317-25. 51. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-90. 52. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483-7. 53. Otani T, Iwasaki M, Sasazuki S, et al. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol Biomarkers Prev 2006;15:690-5. 54. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res 2005;11:3642-6. 55. Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006;130:1865-71. 56. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124:544-60. 57. Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001;96:2992-3003. 58. Wark PA, Wu K, van 't Veer P, et al. Family history of colorectal cancer: A determinant of advanced adenoma stage or adenoma multiplicity? Int J Cancer 2009. 59. Slattery ML, Kerber RA. Family history of cancer and colon cancer risk: the Utah Population Database. J Natl Cancer Inst 1994;86:1618-26. 60. Choi PM, Nugent FW, Schoetz DJ, Jr., et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993;105:418-24. 61. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-95. 62. Rockey DC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet 2005;365:305-11. 63. Winawer SJ, Stewart ET, Zauber AG, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000;342:1766-72. 64. Sung JJ, Lau JY, Young GP, et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008;57:1166-76. 65. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008;149:441-50, W81. 66. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27. 67. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14. 68. Wu GH, Wang YM, Yen AM, et al. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer 2006;6:136. 69. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7. 70. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-71. 71. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7. 72. Mandel JS, Church TR, Ederer F, et al. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-7. 73. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005;129:422-8. 74. Faivre J, Dancourt V, Lejeune C, et al. Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study. Gastroenterology 2004;126:1674-80. 75. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56:210-4. 76. Young GP, St John DJ, Winawer SJ, et al. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroenterol 2002;97:2499-507. 77. Costantini AS, Martini A, Puliti D, et al. Colorectal cancer mortality in two areas of Tuscany with different screening exposures. J Natl Cancer Inst 2008;100:1818-21. 78. Launoy GD, Bertrand HJ, Berchi C, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005;115:493-6. 79. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55. 80. Nakama H, Yamamoto M, Kamijo N, et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999;46:228-31. 81. Young GP, Cole S. New stool screening tests for colorectal cancer. Digestion 2007;76:26-33. 82. Lee KJ, Inoue M, Otani T, et al. Colorectal cancer screening using fecal occult blood test and subsequent risk of colorectal cancer: a prospective cohort study in Japan. Cancer Detect Prev 2007;31:3-11. 83. Selby JV, Friedman GD, Quesenberry CP, Jr., et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-7. 84. Hoff G, Grotmol T, Skovlund E, et al. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. Bmj 2009;338:b1846. 85. Levin TR, Zhao W, Conell C, et al. Complications of colonoscopy in an integrated health care delivery system. Ann Intern Med 2006;145:880-6. 86. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008;135:1899-1906, 1906 e1. 87. Benson VS, Patnick J, Davies AK, et al. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer 2008;122:1357-67. 88. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 2006;101:343-50. 89. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8. 90. Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology 1997;112:17-23. 91. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1-8. 92. Bressler B, Paszat LF, Chen Z, et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology 2007;132:96-102. 93. Bressler B, Paszat LF, Vinden C, et al. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology 2004;127:452-6. 94. Chiu HM, Chang CY, Chen CC, et al. A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut 2007;56:373-9. 95. Fu KI, Sano Y, Kato S, et al. Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study. Endoscopy 2004;36:1089-93. 96. Machida H, Sano Y, Hamamoto Y, et al. Narrow-band imaging in the diagnosis of colorectal mucosal lesions: a pilot study. Endoscopy 2004;36:1094-8. 97. Su MY, Hsu CM, Ho YP, et al. Comparative study of conventional colonoscopy, chromoendoscopy, and narrow-band imaging systems in differential diagnosis of neoplastic and nonneoplastic colonic polyps. Am J Gastroenterol 2006;101:2711-6. 98. Lieberman DA, Faigel DO, Logan JR, et al. Assessment of the quality of colonoscopy reports: results from a multicenter consortium. Gastrointest Endosc 2009;69:645-53. 99. Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Am J Gastroenterol 2006;101:873-85. 100. Anderson ML, Pasha TM, Leighton JA. Endoscopic perforation of the colon: lessons from a 10-year study. Am J Gastroenterol 2000;95:3418-22. 101. Araghizadeh FY, Timmcke AE, Opelka FG, et al. Colonoscopic perforations. Dis Colon Rectum 2001;44:713-6. 102. Iqbal CW, Chun YS, Farley DR. Colonoscopic perforations: a retrospective review. J Gastrointest Surg 2005;9:1229-35: discussion 1236. 103. Luning TH, Keemers-Gels ME, Barendregt WB, et al. Colonoscopic perforations: a review of 30,366 patients. Surg Endosc 2007;21:994-7. 104. Kaltenbach T, Sano Y, Friedland S, et al. American Gastroenterological Association (AGA) Institute technology assessment on image-enhanced endoscopy. Gastroenterology 2008;134:327-40. 105. Rex DK, Helbig CC. High yields of small and flat adenomas with high-definition colonoscopes using either white light or narrow band imaging. Gastroenterology 2007;133:42-7. 106. Gono K, Obi T, Yamaguchi M, et al. Appearance of enhanced tissue features in narrow-band endoscopic imaging. J Biomed Opt 2004;9:568-77. 107. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001;84:1354-62. 108. Muto M, Katada C, Sano Y, et al. Narrow band imaging: a new diagnostic approach to visualize angiogenesis in superficial neoplasia. Clin Gastroenterol Hepatol 2005;3:S16-20. 109. Muto M, Nakane M, Katada C, et al. Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites. Cancer 2004;101:1375-81. 110. East JE, Tan EK, Bergman JJ, et al. Meta-analysis: narrow band imaging for lesion characterization in the colon, oesophagus, duodenal ampulla and lung. Aliment Pharmacol Ther 2008;28:854-67. 111. van den Broek FJ, Reitsma JB, Curvers WL, et al. Systematic review of narrow-band imaging for the detection and differentiation of neoplastic and nonneoplastic lesions in the colon (with videos). Gastrointest Endosc 2009;69:124-35. 112. Group UCCSP. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. Bmj 2004;329:133. 113. Denis B, Ruetsch M, Strentz P, et al. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test. Gut 2007;56:1579-84. 114. UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. Bmj 2004;329:133. 115. Brenner H, Hoffmeister M, Arndt V, et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst;102:89-95. 116. Bureau of Health Promotion DoH, Taiwan. Cancer Control Act. 2003;http://www.bhp.doh.gov.tw/english/category.php?table=rhttp://www.bhp.doh.gov.tw/bhpnet/English/ClassShow.aspx?No=200803260008esearch&page=detail&id=44&pid=96.Jan. 15 2010. 117. Aitken JF, Bain CJ, Ward M, et al. Risk of colorectal adenomas in patients with a family history of colorectal cancer: some implications for screening programmes. Gut 1996;39:105-8. 118. Burt RW. Colon cancer screening. Gastroenterology 2000;119:837-53. 119. Bureau of Health Promotion DoH, Taiwan. Colorectal Cancer Prevention (Chinese). 2003;http://www.bhp.doh.gov.tw/bhpnet/Portal/Them.aspx?No=200802140005.Jan. 15 2010. 120. Tsoi KK, Ng SS, Leung MC, et al. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Aliment Pharmacol Ther 2008;28:353-63. 121. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:659-69. 122. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000;133:573-84. 123. Frazier AL, Colditz GA, Fuchs CS, et al. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-61. 124. Wong JM, Yen MF, Lai MS, et al. Progression rates of colorectal cancer by Dukes' stage in a high-risk group: analysis of selective colorectal cancer screening. Cancer J 2004;10:160-9. 125. Stryker SJ, Wolff BG, Culp CE, et al. Natural history of untreated colonic polyps. Gastroenterology 1987;93:1009-13. 126. Chen TH, Kuo HS, Yen MF, et al. Estimation of sojourn time in chronic disease screening without data on interval cases. Biometrics 2000;56:167-72. 127. Wong WM, Lam SK, Cheung KL, et al. Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer 2003;97:2420-4. 128. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90. 129. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust 2001;175:195-8. 130. East JE, Suzuki N, Stavrinidis M, et al. Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer. Gut 2008;57:65-70. 131. Huneburg R, Lammert F, Rabe C, et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 2009;41:316-22. 132. Lecomte T, Cellier C, Meatchi T, et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005;3:897-902. 133. Rastogi A, Keighley JD, Singh V, et al. Does the Size of Polyp or Learning Effect Impact Ability of Narrow Band Imaging (NBI) in Differentiating Neoplastic and Non-Neoplastic Polyps? Digestive Disease Week 2009. Chicago, IL, U.S., 2009. 134. Subramanian V, Mannath J, Hawkey CJ, et al. Utility of Kudo Pit Pattern for Distinguishing Adenomatous from Non Adenomatous Colonic Lesions In Vivo: Meta-Analysis of Different Endoscopic Techniques. Digestive Disease Week 2009. Chicago, IL, U.S., 2009. 135. Briggs AH, Goeree R, Blackhouse G, et al. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22:290-308. 136. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-8. 137. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-10. 138. Brenner H, Hoffmeister M, Arndt V, et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010;102:89-95. 139. Hunt TL, Luce BR, Page MJ, et al. Willingness to pay for cancer prevention. Pharmacoeconomics 2009;27:299-312. 140. Lejeune C, Dancourt V, Arveux P, et al. Cost-effectiveness of screening for colorectal cancer in France using a guaiac test versus an immunochemical test. Int J Technol Assess Health Care 2010;26:40-7. 141. Heitman SJ, Au F, Manns BJ, et al. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy. Clin Gastroenterol Hepatol 2008;6:912-917 e1. 142. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, et al. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst 2009;101:1412-22. 143. Velho S, Moutinho C, Cirnes L, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 2008;8:255. 144. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-30. 145. Birgisson H, Ghanipour A, Smedh K, et al. The correlation between a family history of colorectal cancer and survival of patients with colorectal cancer. Fam Cancer 2009;8:555-61. 146. Chan JA, Meyerhardt JA, Niedzwiecki D, et al. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. Jama 2008;299:2515-23. 147. Zell JA, Honda J, Ziogas A, et al. Survival after colorectal cancer diagnosis is associated with colorectal cancer family history. Cancer Epidemiol Biomarkers Prev 2008;17:3134-40. 148. Almendingen K, Hofstad B, Vatn MH. Does a family history of cancer increase the risk of occurrence, growth, and recurrence of colorectal adenomas? Gut 2003;52:747-51. 149. Bazzoli F, Fossi S, Sottili S, et al. The risk of adenomatous polyps in asymptomatic first-degree relatives of persons with colon cancer. Gastroenterology 1995;109:783-8. 150. Bureau of Helath Promotion DoH. Taiwan Cancer Registry.http://crs.cph.ntu.edu.tw/main.php?Page=N1.November 24 2009. 151. Nelson DB, McQuaid KR, Bond JH, et al. Procedural success and complications of large-scale screening colonoscopy. Gastrointest Endosc 2002;55:307-14. 152. Taku K, Sano Y, Fu KI, et al. Iatrogenic perforation associated with therapeutic colonoscopy: a multicenter study in Japan. J Gastroenterol Hepatol 2007;22:1409-14. 153. East JE, Suzuki N, Saunders BP. Comparison of magnified pit pattern interpretation with narrow band imaging versus chromoendoscopy for diminutive colonic polyps: a pilot study. Gastrointest Endosc 2007;66:310-6. 154. Tischendorf JJ, Wasmuth HE, Koch A, et al. Value of magnifying chromoendoscopy and narrow band imaging (NBI) in classifying colorectal polyps: a prospective controlled study. Endoscopy 2007;39:1092-6. 155. Pohl J, Nguyen-Tat M, Pech O, et al. Computed virtual chromoendoscopy for classification of small colorectal lesions: a prospective comparative study. Am J Gastroenterol 2008;103:562-9. 156. Kiesslich R, von Bergh M, Hahn M, et al. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. Endoscopy 2001;33:1001-6. 157. Tung SY, Wu CS, Su MY. Magnifying colonoscopy in differentiating neoplastic from nonneoplastic colorectal lesions. Am J Gastroenterol 2001;96:2628-32. 158. Hirata M, Tanaka S, Oka S, et al. Magnifying endoscopy with narrow band imaging for diagnosis of colorectal tumors. Gastrointest Endosc 2007;65:988-95. 159. Sano Y, Ikematsu H, Fu KI, et al. Meshed capillary vessels by use of narrow-band imaging for differential diagnosis of small colorectal polyps. Gastrointest Endosc 2008. 160. O'Leary BA, Olynyk JK, Neville AM, et al. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol 2004;19:38-47. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45080 | - |
dc.description.abstract | 大腸直腸癌是目前世界上最常見的惡性腫瘤之一,也是亞洲地區近年來增加速度最快速的癌症。根據衛生署的統計,目前大腸直腸癌已高居國人十大癌症死因第三名,也是每年新增個案最多的癌症。由於大腸直腸癌有較長的癌前時期與前臨床期,又有一些明確的危險因子,因此不論是初段預防或次段預防都有可以著力的地方。目前衛生署國民健康局也提供五十歲以上民眾接受每兩年一次的糞便潛血檢查並對一等親有大腸直腸癌家族病史之高危險群提供每五年一次的大腸鏡檢。本論文主要的研究主題在於探討現行高危險群篩檢策略的妥當性及藉由決策分析探討以新內視鏡技術篩檢應用於高危險群之可行性。
針對高危險群施以內視鏡篩檢,如能配合影像強化內視鏡技術,預期能夠減少對非腫瘤性病灶的過度治療(over-treatment)與腫瘤性病灶的治療不足(under- treatement),得到較佳的成本效果比。我們的決策分析比較無篩檢、每年糞便潛血檢查、每五年一次之傳統白光內視鏡、染色內視鏡與窄帶內視鏡(narrow band imaging, NBI)五種篩檢策略。 在這個成本效果分析當中,吾人以七階段馬可夫電腦模式來比較各種篩檢策略。假設提供免疫法糞便潛血檢查、傳統白光大腸鏡(white light endoscopy, WLE)、染色內視鏡NBI給大於五十歲高危險群十萬人進行篩檢,直至六十九歲為止,所有在篩檢當中所發現或診斷的腫瘤性病灶均予以切除並依現行監測指針進行追蹤。高危險群的腫瘤性病灶盛行率根據過去台灣內視鏡篩檢的結果與文獻上與一般危險性族群比較之相對風險。轉移速率與機率的估計乃根據過去台灣社區篩檢的結果以及針對高危險群研究的結果。篩檢相關成本資料根據健保局給付規定,而各病期大腸直腸癌的治療費用則以隨機抽樣方式來估算。本成本效果分析研究是根據支付者觀點進行。 研究結果顯示篩檢可以有效降低大腸直腸癌的發生率與死亡率,其中糞便潛血檢查、傳統白光內視鏡、染色內視鏡與NBI內視鏡篩檢,與無篩檢策略相較後大腸直腸癌之發生率分別下降63.8、76.8、80.8及79.9%,死亡率則分別下降63.8、77.3、81.2及80.3%。與無篩檢策略相比之增量效果比(Incremental cost-effectivenss ratio,ICER)分別為每增加一單位之平均餘命需花費美元6,511、2,064、3,072與3,310元。與糞便潛血檢查相比,傳統內視鏡、染色內視鏡及NBI之ICER則分別為美金279、402與394元。敏感度分析顯示大腸直腸腫瘤的盛行率與對大腸鏡檢之順從性、傳統白光內視鏡對小腺瘤之偵測率與敏感度,對於以內視鏡方式進行篩檢之策略的ICER有顯著的影響。雖然影像強化內視鏡與傳統白光內視鏡給付或價格上並無不同,但如影像強化內視鏡相對於傳統白光內視鏡的價格則對以影像強化內視鏡進行篩檢之ICER有顯著影響。根據可接受曲線(accceptability)分析,當願意付出之最高金額(maximum willing to pay)為美金700元或以下時,糞便潛血檢查最符合成本效果,1,000元以上時則以影像強化內視鏡最符合成本效果。 現行以大腸鏡進行大腸直腸癌高危險群的篩檢是妥當且在低增量成本的情況下可以有效降低發生率與死亡率。在合理增加成本之情況下,運用影像強化內視鏡則可進一步提高內視鏡篩檢之成本效果。至於運用影像強化內視鏡於一般危險性族群之可行性則有待更進一步研究。 | zh_TW |
dc.description.abstract | Colorectal cancer (CRC) is one of the most common maligancy worldwide and many of the Asian countries experiences remarkable and rapid rise of CRC incidence in the past decades. According to the national census and cancer registry data, CRC is nowadays the third leading cause of cancer mortality and has the most incident cases among all malignancies in Taiwan. Owing to its long precancerous period and sublinical early stage and identifiable risk factors, there are several points to put our strength in terms of primary and secondary prevention. With many identifiable risk factors which are preventable and modifiable, primary prevention is a feasible way for CRC prevention. Moreover, there are several good tools for CRC screening and early diagnosis which leads to favorable long term outcome. Bureau of Helath Promotion of Department of Health has launched a nation-wide CRC screening program since 2004 which provides biennial fecal occult blood test for average-risk people older than 50 years and 5-yearly primary screening colonoscopy for high-risk population who have CRC family history in their first degree relatives. The focus of this dissertation will be specifically on the research on the appropriateness of current screening policies and elucidate the feasibility of applying new endoscopic technologies for high-risk population via a decision analysis model.
Compared to conventional white light endoscopy, application of IEE for endoscopic screening in high-risk group may be helpful with anticipated reduction of both over-treatment and under-treatment of detected lesions and achieving a better cost-performance. Our decision analysis compared five strategies of CRC screening: no screening, annual fecal occult blood test (FOBT), 5-yearly endoscopic screening with conventional white light endoscopy (WLE), chromoendoscopy and narrow band imaging (NBI). The cost-effectivenss of the screening strategies were compared by using a computer model of seven-state Markov process. A hypothetical 100,000 high-risk population aged 50 years underwent screening with annual immune FOBT, 5-yearly WLE, 5-yearly chromoendoscopy and 5-yearly NBI till the age of 69. All neoplastic lesions detected at screening were resected and received surveillance according to the current guidelines. Prevalence of colorectal neoplasm in high-risk population was estimated according to previous prevalence study in Taiwanese population and literature review of the relative risk in high-risk popualtion. Transition rates and probabilities were estimated from previous population-based studies in general Taiwanese population and also from studies on high-risk population. Cost ensued by screening were obtained from National Health Insurance reimbursement data and stage-specific CRC treatment cost were estimated from sampling of empirical data. The study was conducted based on a health-care payer perspective. Base-case anlysis showed that screening is effective in terms of rduction of CRC incidence and mortality. When compared with no screening strategy, the reduction of incidence using FOBT, WLE, chromoendoscopy and NBI was 63.8、76.8、80.8 and 79.9% and mortaily of 63.8, 77.3, 81.2 and 80.3%. Incremental cost-effectivenss ratio (ICER) using FOBT, WLE, chromoendoscopy and NBI was USD 6,511, 2,064,3,072,and 3,310 per life-year gained compared with no screening strategy and ICER of WLE, chromoendoscopy and NBI was USD 279, 402 and 394 when endoscopic strategies were compared with FOBT. Sensitivity analyses showed that screening with endoscopic modalities was more sensitive to the prevalence of adenoma, the compliance to endoscopy, detection rate and sensitivity of small adenoma by colonoscopy. Though insurance reimbursement among WLE and IEE modalities are not different, screening with IEE modalities was more sensitive to the relative cost compared to WLE. WLE was most cost-effective when WTP was less than USD 700 and IEE was more cost-effective when WTP was greater than USD 1000. Current recommendation of endoscopic screening for high-risk population is optimal as it reduced incidenc and mortality at acceptable incremental costs. Applicaton of IEE can further improve cost-effectiveness of endoscopic screening. Its application in average-risk population need further study. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:03:42Z (GMT). No. of bitstreams: 1 ntu-99-Q93846004-1.pdf: 1872688 bytes, checksum: 6d9634e3b5a7976ad0bfb71b54922bea (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii 英文摘要 v 圖目錄 ix 表目錄 x 第一章 前言 1 第二章 文獻回顧 4 2.1 流行病學 5 2.2 致病機轉與途徑 5 2.3 初段預防與次段預防之角色 7 2.4 危險因子 7 2.5 篩檢策略 9 第三章 研究材料與方法 17 3.1 研究設計與研究對象 18 3.2 大腸直腸腫瘤自然病史之建立 18 3.3 資料收集-參數之決定 22 第四章 研究結果 28 4.1 成本 29 4.2 結果(outcomes) 29 4.3 成本效果分析(Cost-effectivenss analysis) 30 第五章 討論 32 5.1 現行篩檢政策之妥當性 33 5.2 影像強化內視鏡在高危險群之運用與成本效果 33 5.3 與過去其他大腸直腸癌篩檢成本效果分析研究之比較 34 5.4 研究之優勢與限制 35 5.5 現行政策的限制與對於現行政策的建議 37 5.6 結語與未來展望 37 參考文獻 90 附錄 103 | |
dc.language.iso | zh-TW | |
dc.title | 大腸直腸癌篩檢策略之評估 | zh_TW |
dc.title | Evaluation of Strategy of Colorectal Cancer Screening | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-1 | |
dc.description.degree | 博士 | |
dc.contributor.advisor-orcid | ,林肇堂(jawtown@ntu.edu.tw) | |
dc.contributor.oralexamcommittee | 吳明賢(Ming-Shiang Wu),張淑惠(Shu-Hui Chang),吳俊穎(Chun-Ying Wu),楊國卿(Kuo-Ching Yang) | |
dc.subject.keyword | 大腸直腸癌,篩檢,糞便潛血檢查,大腸鏡,影像強化內視鏡,馬可夫模式,成本效果分析, | zh_TW |
dc.subject.keyword | Colorectal cancer (CRC),screening,fecal occult blood test (FOBT),colonoscopy,image enhancing endoscopy (IEE),Markov model,cost-effectivenss analysis, | en |
dc.relation.page | 146 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-02-11 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 1.83 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。